Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia

NCT07622329 is registered in ClinicalTrials.gov with The General Hospital of Western Theater Command as lead sponsor.

NCT NCT07622329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07622329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia
Lead sponsor
The General Hospital of Western Theater Command
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 18, 2026
Completion date
June 30, 2027
Enrollment
4 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocytopenic purpura, immune